One Of The Biggest Canned Tuna Recalls In US History Originated In Hawaii
Included in our list of the biggest tuna recalls to ever happen in the U.S., 40 million cans of tuna produced at a Bumble Bee plant (although other brands were involved) located in Honolulu, Hawaii, were recalled after several consumers found puncture marks in the steel cans. The damaged cans of tuna made their way to several states, including New York and Washington. Defects in cans can decrease the safety of canned goods, enabling air exposure that can foster the growth of dangerous bacteria. While the punctured cans led to spoilage, no illnesses were reported.
Read more: 17 Canned Sardine Brands Ranked Worst To Best
While food recalls are subject to rigorous investigation by food manufacturers as well as agencies like the FDA and USDA, it's not always possible to determine the cause of a defect. In the case of the 1982 canned tuna recall originating in Honolulu, FDA investigators were able to pinpoint a likely cause for the punctures found in cans of Bumble Bee tuna and other brands. It's believed that wire baskets used during the heating of the cans were faulty and may have created holes in the steel. Because these punctures were hidden by product labeling, consumers were unable to detect them and only discovered the issue upon opening the can.
At the time , investigators claimed that canned tuna had a lower chance of developing harmful bacteria like botulism because of the heat treatment that takes place during the canning process. However, a recent recall involving several brands of canned tuna with defective lids was enacted over concerns about potential Clostridium botulinum contamination, which can be life-threatening. That's why consumers are urged to discard all recalled products without opening to prevent food poisoning. Along with heeding the instructions that accompany recalls, consumers must also know the common signs of canned food spoilage. In addition to visible damage to the can itself, foul odors, discoloration, and bubbling also indicate bacterial growth.
Read the original article on Mashed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Porosome Therapeutics Announces Breakthrough Alzheimer's Discoveries
BOSTON--(BUSINESS WIRE)-- Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced key advancements in its first-in-class, disease-modifying neurological platform, which will transform Alzheimer's Disease (AD) research and treatment by offering a new approach that goes beyond symptom management. Following the recent FDA validation of organoid-based studies, the company has demonstrated a relatively rapid reduction of the Alzheimer's pathology in AD human brain organoids treated with its principal therapy; shown a significant reduction of the Tau protein, acknowledged by the Food and Drug Administration (FDA) as an AD biomarker, in other studies; and established new classes of AD therapeutics. Implementing the company's signature ' Reprogram, Restore, and Rescue ' strategy, researchers introduce healthy porosomes – neuronal secretory nanomachines – into diseased neurons to target the root causes of AD. By restoring the neuron's secretory and metabolic systems, Porosome Therapeutics' first-of-its-kind approach addresses the cellular function of AD rather than traditional symptom management. 'Unlike therapies that merely dissolve beta amyloid plaques, our platform directly targets the core biological dysfunctions of Alzheimer's, restoring both neurotransmission and metabolic integrity,' said Guillermo Marmol, CEO, Porosome Therapeutics. 'Given Alzheimer's is a serious and life-threatening disease with no effective treatment options, and based on our ability to deliver quantifiable, biomarker-driven improvements, including Tau reduction and disease reversal in human brain organoids, we are actively exploring the FDA's accelerated approval pathway.' In recent studies, the company's approach to porosome restoration has been shown to significantly reduce Tau protein levels – a key FDA-approved biomarker of Alzheimer's. The FDA's recent approval of the Tau test is a landmark development in the research for AD therapies, catalyzed by the groundbreaking science of Porosome Therapeutics. Furthermore, the company's therapeutic approach has been validated using FDA-recommended human brain organoid models, demonstrating fast clinical results with a significant reversal of Alzheimer's pathology shown within two weeks. Organoid models are three-dimensional cell cultures derived from stem cells that mimic the structure and function of human organs. 'When using human brain organoids, we're able to observe the molecular activity of the porosome at an entirely new scale,' said Bhanu P. Jena, PhD, Founder and Chairman, Porosome Therapeutics, and a distinguished cell biologist known for his discovery of the porosome nanomachine, the secretory portal of the cell. 'The ability to create an immense impact in just two weeks is a promising step forward and marks an important milestone as we advance the future of Alzheimer's research and care.' In a complementary development, the company is leveraging artificial intelligence (AI) to design proprietary decoy peptides that target and neutralize the toxic beta amyloid peptide (1-42), which is known for disrupting protein-protein interactions within the neuronal porosome complex and impairing neurotransmitter release. These specially designed AI-decoys bind more strongly to the beta amyloid (1-42), diverting the peptide from interfering with essential porosome functions. With these advances, Porosome Therapeutics has identified three distinct therapeutic classes for AD: Small Molecules and Peptides – Cross the blood-brain barrier to restore mitochondrial function. Biologics – Reconstitute the porosome complex to reverse neuronal secretory dysfunction. AI-Designed Peptides – Decoy peptides designed by AI to neutralize beta amyloid peptides (1-42) and protect neurotransmission. Porosome Therapeutics has expanded its portfolio of products to reflect these breakthroughs and the company's commitment to advancing novel treatment modalities beyond the current standard of care. About Porosome Therapeutics, Inc. Porosome Therapeutics, Inc. is a biopharmaceutical company based in Boston that leverages the groundbreaking discovery of the porosome — the cell's essential secretory machinery. The company employs innovative technologies to identify and develop proprietary therapeutics aimed at currently undruggable porosome proteins linked to secretory and hydration disorders such as cystic fibrosis, diabetes, and cancer. Porosome Therapeutics is the first company to employ a technology platform dedicated to creating novel therapies targeting the porosome, recognized as the universal secretory machinery in cells. This platform is built on decades of research and is supported by over 200 published studies, proving effective against various serious diseases involving secretory defects. The platform focuses on highly specific nanobody-mediated therapies, aiming to significantly reduce drug side effects. Porosome Therapeutics' work on Alzheimer's Disease is carried out through a subsidiary, NeuroTher LLC.
Epoch Times
an hour ago
- Epoch Times
FDA Issues Update on Most Serious Recall for Certain Ventilators
The Food and Drug Administration (FDA) issued a notice warning that medical ventilators made by Philips Respironics are still under a Class I recall due to the potential for serious injury or death. The agency noted that the recall notice for the company's V30, A30, and A40 ventilators, which are used for obstructive sleep apnea (OSA), primarily 'involves correcting devices and does not involve removing them from where they are used or sold.'
Boston Globe
an hour ago
- Boston Globe
The FDA is targeting orange juice. Here's why, and what the science says.
Orange juice contains nutrients including calcium and Vitamin C. But some nutritionists argue that's not enough to make up for the unnecessary calories and natural sugars. 'Juices are a dilemma,' said Peter Lurie, the executive director of the nonprofit Center for Science in the Public Interest, which advocates for a healthy and safe food supply. Get Winter Soup Club A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter. Enter Email Sign Up The American Academy of Pediatrics recommends instead eating real fruit, which contains more fiber than juice. The association advises against giving fruit juice to infants except to manage constipation. It also advises limiting how much juice parents should give older children, such as no more than 4 ounces per day for kids 1 to 3 years old. Advertisement 'If you're going to have a small amount of juice, it's not going to be anything that anybody's going to worry about,' said Marion Nestle, a retired professor of nutrition, food studies and public health at New York University who called fruit juices 'delicious.' 'When you worry about juice is when it's in large amounts,' she added. Advertisement Even though leading orange juice brands do not contain added sugars, high levels of natural sugars can still be harmful, some experts said. 'Orange juice is sugar water,' said Barry Popkin, a professor of nutrition at the University of North Carolina. 'Every juice is essentially sugar water.' Once touted as part of a balanced breakfast, Americans are souring on orange juice. Consumers have gravitated toward other beverage options seen as healthier. Prices have risen. Production has stalled. And this has become a problem for Florida's orange producers. The sugar content of the fruit grown in the state has been steadily dropping due to a bacterial disease afflicting the crop, exacerbated after Hurricane Irma struck in 2017. In 2022, Florida trade groups representing the state's citrus growers and citrus juice industry petitioned the FDA to lower the minimum fruit sugar levels for pasteurized orange juice. The FDA sets a minimum standard for the sugar content in order to call a drink 'pasteurized orange juice,' the kind commonly sold at grocery stores without added sugars. If manufacturers fall below that threshold, they are essentially no longer allowed to call their products 'pasteurized orange juice." Florida orange industry groups said lowering that threshold would protect their business and reduce orange imports from other countries while going unnoticed by consumers. Sugar per serving would lower from 18 grams to 17 grams, according to nutritional label samples provided to the FDA by the industry. Other nutrients would be largely unaffected to the change. Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary both pledged to examine this proposal during congressional hearings when pressed by Sen. Ashley Moody (R-Florida). Advertisement Some nutrition experts said if Kennedy wanted to advance his 'Make America Healthy Again' agenda, which included pledges to improve the diets of children, he should champion more sweeping regulations broadly targeting sugars and sodium. 'If one is serious about sugar in the American diet, we need an across the board approach,' Lurie said.
